Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil : a multicenter study
dc.contributor.author | Callefi, Luciana Azevedo | pt_BR |
dc.contributor.author | Villela-Nogueira, Cristiane Alves | pt_BR |
dc.contributor.author | Tenore, Simone de Barros | pt_BR |
dc.contributor.author | Carnauba Junior, Dimas | pt_BR |
dc.contributor.author | Coelho, Henrique Sérgio Moraes | pt_BR |
dc.contributor.author | Pinto, Paulo de Tarso Aparecida | pt_BR |
dc.contributor.author | Nabuco, Leticia Cancella | pt_BR |
dc.contributor.author | Pessôa, Mário Guimarães | pt_BR |
dc.contributor.author | Ferraz, Maria Lucia Cardoso Gomes | pt_BR |
dc.contributor.author | Ferreira, Paulo Roberto Abrão | pt_BR |
dc.contributor.author | Martinelli, Ana de Lourdes Candolo | pt_BR |
dc.contributor.author | Chachá, Silvana Gama Florencio | pt_BR |
dc.contributor.author | Ferreira, Adalgisa de Souza Paiva | pt_BR |
dc.contributor.author | Costa, Alessandra Porto de Macedo | pt_BR |
dc.contributor.author | Brandão-Mello, Carlos E. | pt_BR |
dc.contributor.author | Álvares-da-Silva, Mário Reis | pt_BR |
dc.contributor.author | Reuter, Tania Queiroz | pt_BR |
dc.contributor.author | Ivantes, Cláudia Alexandra Pontes | pt_BR |
dc.contributor.author | Perez, Renata de Mello | pt_BR |
dc.contributor.author | Mendes-Corrêa, Maria Cássia Jacintho | pt_BR |
dc.date.accessioned | 2018-10-27T03:12:23Z | pt_BR |
dc.date.issued | 2017 | pt_BR |
dc.identifier.issn | 1980-5322 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/184032 | pt_BR |
dc.description.abstract | OBJECTIVE: To evaluate the effectiveness and safety of first-generation protease inhibitors for the treatment of genotype 1 hepatitis C virus-infected patients at Brazilian reference centers. METHODS: This multicenter cross-sectional study included hepatitis C virus genotype 1 monoinfected patients treated with Peg-interferon, ribavirin, and either boceprevir (n=158) or telaprevir (n=557) between July 2013 and April 2014 at 15 reference centers in Brazil. Demographic, clinical, virological, and adverse events data were collected during treatment and follow-up. RESULTS: Of the 715 patients, 59% had cirrhosis and 67.1% were treatment-experienced. Based on intention-totreat analysis, the overall sustained viral response was 56.6%, with similar effectiveness in both groups (51.9% for boceprevir and 58% for telaprevir, p=0.190). Serious adverse events occurred in 44.2% of patients, and six deaths (0.8%) were recorded. Cirrhotic patients had lower sustained viral response rates than non-cirrhotic patients (46.9% vs. 70.6%, po0.001) and a higher incidence of serious adverse events (50.7% vs. 34.8%, po0.001). Multivariate analysis revealed that sustained viral response was associated with the absence of cirrhosis, viral recurrence after previous treatment, pretreatment platelet count greater than 100,000/mm3, and achievement of a rapid viral response. Female gender, age465 years, diagnosis of cirrhosis, and abnormal hemoglobin levels/platelet counts prior to treatment were associated with serious adverse events. CONCLUSION: Although serious adverse events rates were higher in this infected population, sustained viral response rates were similar to those reported for other patient cohorts. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | Clinics (São Paulo). São Paulo. Vol. 72, n. 6 (June 2017), p. 378-385 | pt_BR |
dc.rights | Open Access | en |
dc.subject | Proteínas recombinantes | pt_BR |
dc.subject | Protease inhibitors | en |
dc.subject | Safety | en |
dc.subject | Hepatite C crônica | pt_BR |
dc.subject | Antivirais | pt_BR |
dc.subject | Hepatitis C | en |
dc.subject | RNA viral | pt_BR |
dc.subject | Chronic | en |
dc.subject | Therapeutics | en |
dc.subject | Hepacivirus | pt_BR |
dc.subject | Meia-idade | pt_BR |
dc.subject | Brasil | pt_BR |
dc.title | Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil : a multicenter study | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001078955 | pt_BR |
dc.type.origin | Nacional | pt_BR |
Files in this item
This item is licensed under a Creative Commons License
-
Journal Articles (39074)Health Sciences (10539)